le LUMACAFTOR et l'IVACAFTOR, 2 médicaments développés à l'origine pour la mucoviscidose et ayant un effet agoniste du canal hERG, pourraient devenir les nouveaux traitements du syndrome du QT long de type 2 (où ce canal est défaillant) c'est fou non ? htt
1,151 followers
565 followers
From patient-specific induced pluripotent stem cells to clinical translation in long QT syndrome Type 2. https://t.co/17Dn2l0abH https://t.co/FC6Zp5edmE
7,198 followers
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…
2,655 followers
RT @SilCastelletti: Just published! @ESC_Journals #EHJ Our first in-human study on Lumacaftor as new more specific and patient-tailored the…